Vasa Therapeutics Seeks Investor Spotlight for Novel Heart Therapies

ENCINITAS, CA – February 12, 2026 – Clinical-stage biotechnology company Vasa Therapeutics is set to take the virtual stage at the prestigious 36th Annual Oppenheimer Life Sciences Conference later this month, a move widely seen as a pivotal moment for the company as it seeks to secure funding and partnerships for its innovative pipeline targeting cardiovascular and age-related diseases.

Company CEO Dr. Artur Plonowski and Chief Medical Officer Dr. Noreen Henig will present to an audience of institutional investors, analysts, and industry stakeholders on February 26th. For a private, clinical-stage company like Vasa, this presentation is more than a calendar entry; it is a strategic platform to articulate its scientific vision and translate its clinical progress into investor confidence.

Headquartered in Encinitas, California, with operations in Wroclaw, Poland, Vasa Therapeutics is focused on what it calls “first-in-class innovation” for conditions where treatment options are limited and patient needs are high. The company's participation in the Oppenheimer conference signals its readiness to move to the next phase of its corporate growth, fueled by promising early data and a clear strategic direction.

A Strategic Pitch for Series A

The timing of the Oppenheimer presentation is critical. Vasa Therapeutics is currently in the process of raising its Series A funding round, a crucial step to finance the costly and complex mid-stage clinical trials required for drug approval. The company successfully closed a $6 million seed funding round in January 2024, led by Orphinic Scientific SA, and has skillfully supplemented its capital with an additional $2.3 million in non-dilutive grants, bringing its total seed funding to over $11 million.

This initial capital has been instrumental in advancing the company’s lead asset, VS-041, through early human trials. Now, the one-on-one meetings scheduled with investors at the conference represent a prime opportunity to secure the larger-scale investment necessary to propel its pipeline forward. For biotechs in this phase, conferences like Oppenheimer's are less about publicity and more about substance, providing a direct channel to the specialized venture capitalists and institutional funds that underwrite the future of medicine.

A strong performance can validate the company’s strategy and build momentum for a successful funding round, while the insights gained from investor questions can help refine its long-term commercialization plans. The presentation will be a test of the leadership's ability to convey a complex scientific narrative into a compelling investment thesis.

Targeting the Unmet Needs of an Aging Heart

At the heart of Vasa's pitch is its lead drug candidate, VS-041, a novel therapy for Heart Failure with Preserved Ejection Fraction (HFpEF). HFpEF is a notoriously difficult-to-treat form of heart failure that affects millions globally, particularly the elderly. The condition is characterized by a stiffening of the heart muscle, which prevents it from filling with blood properly, leading to debilitating symptoms and poor outcomes. Despite its prevalence, there are few treatments that effectively modify the underlying disease.

Vasa's approach with VS-041 is highly targeted. The drug is a narrow-spectrum inhibitor of MMP-2 and MMP-9, enzymes that are implicated in the cardiac fibrosis and inflammation that drive HFpEF. By aiming for a “personalized medicine-based therapy,” the company hopes to deliver a more effective treatment than the broader-acting drugs currently available.

The strategy is already showing promise. VS-041 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), a status granted to drugs that show potential to address serious unmet medical needs. The company also successfully completed a first-in-human Phase 1 study in 70 healthy volunteers, where the drug was found to be safe and well-tolerated. It is now enrolling patients in a Proof-of-Mechanism study to further validate its therapeutic approach in HFpEF patients.

Beyond its lead program, Vasa has engineered a broader pipeline targeting other significant age-related conditions. Its long-acting Apelin analogs are being developed for peripheral arterial disease (PAD), neuromuscular disorders, and sarcopenia—the age-related loss of muscle mass. These candidates have shown potential in preclinical models to not only preserve muscle but also to improve cardiac output, highlighting the company’s platform approach to tackling the interconnected pathologies of aging.

Veteran Leadership Steering a First-in-Class Vision

Guiding Vasa Therapeutics through the treacherous waters of biotech drug development is a leadership team with decades of experience at both nimble startups and pharmaceutical giants. The combined expertise of CEO Dr. Artur Plonowski and CMO Dr. Noreen Henig provides a foundation of credibility that investors will be scrutinizing closely.

Dr. Plonowski, a co-founder of the company, has over 20 years of experience in drug discovery and development, with a track record that includes leadership roles at Allergan, Takeda, and Exelixis. He previously served as President and CEO of Aardvark Therapeutics, successfully guiding that company's lead asset into clinical trials. His expertise lies in translating scientific concepts into viable corporate and development strategies.

Dr. Henig brings an equally impressive resume as a physician-scientist with deep expertise in clinical trial execution and regulatory strategy. Her career includes roles as CMO at Breath Therapeutics, which was acquired by Zambon, and as Chief Development Officer at ProQR Therapeutics, where she was instrumental in the company’s transition from a private to a public entity. With prior experience at Gilead Sciences and a distinguished academic career at Stanford University, Dr. Henig understands precisely what is required to move a drug from the laboratory bench to the patient’s bedside.

This blend of corporate strategy and clinical execution is a powerful asset for a young company aiming to disrupt established treatment paradigms. Their collective experience in navigating both scientific hurdles and financial markets will be central to their message at the upcoming conference.

Navigating a Competitive and Promising Landscape

Vasa Therapeutics is entering a highly competitive arena. The markets for heart failure, PAD, and sarcopenia are crowded with large pharmaceutical companies like Novartis and AstraZeneca, as well as a host of other innovative biotechs. However, the significant unmet medical need in these areas, particularly for disease-modifying therapies, leaves ample room for true innovation.

Vasa's strategy is to differentiate itself through a focus on novel, “first-in-class” mechanisms. Instead of developing another incremental improvement, the company is betting on its proprietary know-how and computational chemistry platform to create new standards of care. This high-risk, high-reward approach is what attracts biotech investors looking for the next major breakthrough.

To accelerate its progress, the company has formed strategic partnerships, such as its collaboration with Quotient Sciences. This partnership leverages an integrated platform for drug manufacturing and clinical testing, allowing Vasa to move VS-041 into and through its Phase 1 trial with greater speed and efficiency. As Vasa's leadership prepares for their presentation, they will be armed not just with promising science, but with a clear, well-executed plan to navigate the path ahead.